| Therapeutic | Duvortuxizumab |
| Target 1 | CD19 |
| Heavy Chain 1 | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS |
| Light Chain 1 | ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | CD3E |
| Heavy Chain 2 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS |
| Light Chain 2 | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Bispecific scFv with Crossover |
| Isotype | na |
| Highest Clinical Trial (Aug '23) | Phase-I |
| Estimated Status (Aug '23) | Discontinued |
| Recorded Developmental Technology | Dual-Affinity Re-Targeting Technology |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Janssen Biotech, MacroGenics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Diffuse large B cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
